USA Penthrox Update & USA Respiratory Update
9 August 2016
ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update
USA : Penthrox update
Medical Developments International (ASX: MVP) advises it has received a written response to its meeting request by the Food & Drug Administration (FDA) in the United States of America. On the basis of the FDA’s written response, MVP has a clearer understanding of the steps required and data needed to get Penthrox approved for sale in the USA.
Amongst certain other requirements, MVP will undertake a second Phase III Pivotal Clinical Trial in the USA for ‘Acute Trauma Pain’. We expect our USA based trial will include an appropriate mix of ethnically diversified patients.
For details relating to the full ASX release please click on the following link ASX Announcement_USA-Penthrox Update
MVP signs Respiratory deal in the United States.
Medical Developments International Limited (ASX: MVP) is delighted to announce that it has agreed a distribution deal with Cardinal Health Inc. for the distribution of its range of ‘Space Chamber’ anti-static Respiratory Devices in the United States of America (USA).
Cardinal Health is a leader in global pharmaceutical sourcing and distribution services. As one of the largest healthcare supply chains in North America, Cardinal Health Inc. is headquartered in Dublin, Ohio. Cardinal Health, Inc. (NYSE: CAH) is a $103 billion health care services company.
For details relating to the full ASX release please click on the following link ASX Announcement_USA-MVP signs respiratory deal in the USA